Description

Qiagen’s New CEO Just Sold His Last Company For $9.25 Billion—Is Another Mega Deal Coming?

Qiagen has suddenly become one of the more closely watched names in European healthcare M&A. The molecular diagnostics and life-sciences company has appointed Jonathan Pratt as CEO effective September 1, just weeks after he helped steer Filtration Group through its $9.25 billion cash sale to Parker-Hannifin. His arrival coincides with an already active strategic review at Qiagen, where private-equity firms including EQT and KKR are reportedly examining potential bids and have been given access to a data room for due diligence. Bloomberg previously reported that some interested parties had considered offers of at least $50 per share. Yet this is not simply a takeover story. Qiagen is profitable, cash-generative and continuing to invest in automation, digital PCR, bioinformatics and diagnostics while forecasting an improvement in growth during the second half of 2026.